These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37398579)

  • 1. Psychedelics and workplace harm.
    Viña SM; Stephens AL
    Front Psychiatry; 2023; 14():1186541. PubMed ID: 37398579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.
    Sexton JD; Nichols CD; Hendricks PS
    Front Psychiatry; 2019; 10():896. PubMed ID: 32116806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.
    Hendricks PS; Thorne CB; Clark CB; Coombs DW; Johnson MW
    J Psychopharmacol; 2015 Mar; 29(3):280-8. PubMed ID: 25586402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between lifetime classic psychedelic use and markers of physical health.
    Simonsson O; Sexton JD; Hendricks PS
    J Psychopharmacol; 2021 Apr; 35(4):447-452. PubMed ID: 33719688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review.
    Zeifman RJ; Singhal N; Breslow L; Weissman CR
    ACS Pharmacol Transl Sci; 2021 Apr; 4(2):436-451. PubMed ID: 33860173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The acute effects of classic psychedelics on memory in humans.
    Healy CJ
    Psychopharmacology (Berl); 2021 Mar; 238(3):639-653. PubMed ID: 33420592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience.
    Palmer M; Maynard OM
    Harm Reduct J; 2022 Jul; 19(1):81. PubMed ID: 35871679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.
    Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB
    J Affect Disord; 2023 Apr; 326():105-110. PubMed ID: 36720405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classic psychedelics, health behavior, and physical health.
    Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB
    Ther Adv Psychopharmacol; 2022; 12():20451253221135363. PubMed ID: 36465958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.
    Mellner C; Dahlen M; Simonsson O
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality.
    Jones GM; Nock MK
    Sci Rep; 2022 Oct; 12(1):16976. PubMed ID: 36216840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study.
    Révész D; Ona G; Rossi GN; Rocha JM; Dos Santos RG; Hallak JEC; Alcázar-Córcoles MÁ; Bouso JC
    Front Psychiatry; 2021; 12():687546. PubMed ID: 34220590
    [No Abstract]   [Full Text] [Related]  

  • 18. Reducing the Harms of Nonclinical Psychedelics Use Through a Peer-Support Telephone Helpline.
    Pleet MM; White J; Zamaria JA; Yehuda R
    Psychedelic Med (New Rochelle); 2023 Jun; 1(2):69-73. PubMed ID: 37360327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.
    Gorman I; Nielson EM; Molinar A; Cassidy K; Sabbagh J
    Front Psychol; 2021; 12():645246. PubMed ID: 33796055
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.